OGNOrganon & Co.

OGN Stock Price, Valuation & Chart | Organon & Co.

Compare

$13.770+0.01 (+0.04%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - General OGN intrinsic value OGN calculated fair value vs price

Overview Financials Dividends Ratios

OGN Historical price chart

OGN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.62B

PE Ratio4.11

EPS3.35

Trading Volume3.63M

Today's High/Low13.78/13.76

Dividend Yield0.58

52 Week High/Low13.79/5.69

Shares Outstanding262.61M

OGN Financial Statement

OGN Analyst ratings

OGN Analysis & performance metrics

OGN Company profile

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its…

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such…

OGN Management team

Name

Position

Daniel Karp

Chief Strategy Officer & Head of Corporate Development

Aaron Falcione

Executive Vice President & Chief Human Resources Officer

Vittorio Nisita

Executive Vice President & Head of Enterprise Services and Solutions

Carrie Smith Cox

Executive Chairman of the Board

Joseph T. Morrissey Jr.CEO

Interim Chief Executive Officer & Executive Vice President and Head of Manufacturing & Supply

Jennifer Halchak

Head of Investor Relations

Matthew M. Walsh C.F.A.CFO

Executive Vice President & Chief Financial Officer

Juan Camilo Arjona Ferreira M.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Name

Position

Daniel Karp

Chief Strategy Officer & Head of Corporate Development

Aaron Falcione

Executive Vice President & Chief Human Resources Officer

Vittorio Nisita

Executive Vice President & Head of Enterprise Services and Solutions

Carrie Smith Cox

Executive Chairman of the Board

Joseph T. Morrissey Jr.CEO

Interim Chief Executive Officer & Executive Vice President and Head of Manufacturing & Supply

Jennifer Halchak

Head of Investor Relations

Matthew M. Walsh C.F.A.CFO

Executive Vice President & Chief Financial Officer

Juan Camilo Arjona Ferreira M.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Management Team

Daniel Karp

Chief Strategy Officer & Head of Corporate Development

Aaron Falcione

Executive Vice President & Chief Human Resources Officer

Vittorio Nisita

Executive Vice President & Head of Enterprise Services and Solutions

Carrie Smith Cox

Executive Chairman of the Board

Joseph T. Morrissey Jr.CEO

Interim Chief Executive Officer & Executive Vice President and Head of Manufacturing & Supply

Jennifer Halchak

Head of Investor Relations

Matthew M. Walsh C.F.A.CFO

Executive Vice President & Chief Financial Officer

Juan Camilo Arjona Ferreira M.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Management

Daniel Karp

Chief Strategy Officer & Head of Corporate Development

Aaron Falcione

Executive Vice President & Chief Human Resources Officer

Vittorio Nisita

Executive Vice President & Head of Enterprise Services and Solutions

Carrie Smith Cox

Executive Chairman of the Board

Joseph T. Morrissey Jr.CEO

Interim Chief Executive Officer & Executive Vice President and Head of Manufacturing & Supply

Jennifer Halchak

Head of Investor Relations

Matthew M. Walsh C.F.A.CFO

Executive Vice President & Chief Financial Officer

Juan Camilo Arjona Ferreira M.D.

Executive Vice President, Head of Research & Development and Chief Medical Officer

Total 8 executives

OGN Frequently asked questions

What is Organon & Co. (OGN) Stock Price?

Current stock price of Organon & Co. (OGN) stock is $13.770. The stock price is +0.04% higher in the session. The intraday range can be seen from this page. Volume of Organon & Co. (OGN) stock is 3.63M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Organon & Co. (OGN) stock price going up or down today?

The stock price of Organon & Co. (OGN) can change with earnings, company news, and overall market sentiment. Organon & Co. operates in the Healthcare / Drug Manufacturers - General market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Organon & Co. stock expensive at its current price?

Whether Organon & Co. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for OGN on this page is 4.11. EPS on this page is 3.35. Compare those figures with peers and growth expectations before deciding if the current Organon & Co. price is justified.

How has the stock price of Organon & Co. (OGN) performed historically?

Historical performance for Organon & Co. (OGN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how OGN reacted to past earnings and market events.

Should I buy Organon & Co. (OGN) stock, at this price?

Buying Organon & Co. (OGN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.